Low intrinsic agonism and balanced pathway modulation distinguish an M1 muscarinic receptor positive allosteric modulator lacking cholinergic adverse effects

ABSTRACT: Positive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (mAChR) have progressed into clinical trials for cognitive disorders, such as Alzheimer’s disease and schizophrenia. This work provides a mechanistic framework for differentiating M1 PAM pharmacology beyond intrinsic agonism alone and may inform the design of safer M1-targeted therapeutics.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Hek-293 Cell

SUBMITTER: Laura Dagley  

LAB HEAD: John Scott

PROVIDER: PXD074843 | Pride | 2026-07-06

REPOSITORIES: Pride